MedTrace Logo

Baclofen for the Treatment of Cocaine Dependence - 1

NCT00082485 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Baclofen

Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Liza Gorgon, M.A. · VA Maryland Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00082485 on ClinicalTrials.gov